MARK2 and neoplasm: Sorafenib is a multitarget inhibitor for suppressing tumor angiogenesis and proliferation, the targets including some serine/threonine kinases, such as C-Raf, wildtype B-Raf, and mutant B-Raf, as well as some receptor tyrosine kinases, such as VEGFR 1-3, PDGFR, and c-KIT [33].